A
Antonio Tavoni
Researcher at University of Pisa
Publications - 131
Citations - 3671
Antonio Tavoni is an academic researcher from University of Pisa. The author has contributed to research in topics: Population & Vasculitis. The author has an hindex of 30, co-authored 124 publications receiving 3166 citations. Previous affiliations of Antonio Tavoni include Sapienza University of Rome.
Papers
More filters
Journal ArticleDOI
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
S. De Vita,Luca Quartuccio,Miriam Isola,Cesare Mazzaro,Patrizia Scaini,M. Lenzi,Mauro Campanini,C. Naclerio,Antonio Tavoni,M. Pietrogrande,Clodoveo Ferri,Maria Teresa Mascia,Paola Masolini,Alen Zabotti,M. Maset,Dario Roccatello,Al Zignego,Pietro Pioltelli,Armando Gabrielli,Davide Filippini,Oreste Perrella,S. Migliaresi,Massimo Galli,Stefano Bombardieri,Giuseppe Monti +24 more
TL;DR: RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy.
Journal ArticleDOI
Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients
Chiara Baldini,Pasquale Pepe,Luca Quartuccio,Roberta Priori,E. Bartoloni,Alessia Alunno,Angelica Gattamelata,M. Maset,M. Modesti,Antonio Tavoni,Salvatore De Vita,Roberto Gerli,Guido Valesini,Stefano Bombardieri +13 more
TL;DR: This study confirmed that the prevalence of the pSS high-risk subset for severe systemic manifestations is ∼15%.
Journal ArticleDOI
Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients
Claudio Vitali,Gianluigi Palombi,Chiara Baldini,Maurizio Benucci,Stefano Bombardieri,Michele Covelli,Nicoletta Del Papa,Salvatore De Vita,Oscar Massimiliano Epis,Franco Franceschini,Roberto Gerli,Marcello Govoni,Susanna Maddali Bongi,Wanda Maglione,Sergio Migliaresi,Carlomaurizio Montecucco,Maddalena Orefice,Roberta Priori,Antonio Tavoni,Guido Valesini +19 more
TL;DR: The SSDDI is an adequate instrument to objectively measure damage in patients with SS, and that the SSDAI is a valid tool to measure disease activity when used either as a single-state index or as a transition index.
Journal ArticleDOI
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.
M. Pietrogrande,Salvatore De Vita,Anna Linda Zignego,Pietro Pioltelli,Domenico Sansonno,Salvatore Sollima,Fabiola Atzeni,Francesco Saccardo,Luca Quartuccio,S. Bruno,Raffaele Bruno,Mauro Campanini,Marco Candela,Laura Castelnovo,Armando Gabrielli,G.B. Gaeta,Piero Marson,Maria Teresa Mascia,Cesare Mazzaro,Francesco Mazzotta,Pier Luigi Meroni,Carlomaurizio Montecucco,Elena Ossi,Felice Piccinino,Daniele Prati,Massimo Puoti,Piersandro Riboldi,Agostino Riva,Dario Roccatello,Evangelista Sagnelli,Patrizia Scaini,Salvatore Scarpato,Renato Alberto Sinico,Gloria Taliani,Antonio Tavoni,Eleonora Bonacci,Piero Renoldi,Davide Filippini,Piercarlo Sarzi-Puttini,Clodoveo Ferri,Giuseppe Monti,Massimo Galli +41 more
TL;DR: A core set of recommendations for the treatment of HCV-associated mixed cryoglobulinemia syndrome is defined by combining current evidence from clinical trials and expert opinion, and may be useful as provisional guidelines for the management of MCS.
Journal ArticleDOI
Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Clodoveo Ferri,Patrice Cacoub,Cesare Mazzaro,Dario Roccatello,Patrizia Scaini,Marco Sebastiani,Antonio Tavoni,Anna Linda Zignego,S. De Vita +8 more
TL;DR: Rituximab may be regarded as useful and safe pathogenetic treatment of cryoglobulinemic vasculitis and the actual role of this drug should be definitely confirmed by randomized controlled trials, as well as its position in the therapeutical strategy, mainly with respect to antiviral treatment in HCV-associated MCs.